We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

I'm ok with this

2019 Press Releases | Media | Grünenthal Group

Discover Grünenthal


Aachen, Germany, and Melbourne, Australia, 10 September 2019 – Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in allogeneic cellular medicines for inflammatory diseases, today announced that they have entered into a strategic partnership to develop and commercialise MPC-06-ID, a Phase III allogeneic cell therapy candidate for the treatment of chronic low back pain due to degenerative disc disease in patients who have exhausted conservative treatment options. Under the partnership, Grünenthal will have exclusive commercialisation rights to MPC-06-ID for Europe and Latin America.


Brussels/Aachen, 6 September 2019. One in five European citizens suffers from chronic pain. For this reason, research in pain is more important than ever. During the Congress of the European Pain Federation EFIC®, four young scientists presented the results of research projects that explore creative approaches to improving the lives of patients in pain.


Aachen, Germany, and Brisbane, Australia, 03 September 2019 – Grünenthal, a global leader in pain research and management, and UniQuest, The University of Queensland’s commercialisation company, today announced they have entered into a collaboration to develop novel, non-opioid drug therapies derived from the group of alpha-conotoxins as analgesic and disease modifying treatments of chronic neuropathic pain. The project’s scientific foundation was laid at The University of Queensland (UQ) by Dr. Richard Clark from the School of Biomedical Sciences in the Faculty of Medicine. The collaboration combines the expertise of UQ in target and peptide – specifically conotoxin – drug discovery and Grünenthal’s long-standing expertise in bringing innovative treatments to people living with pain worldwide.


Aachen, 13. August 2019 – Die Geschäftsführung und der Betriebsrat von Grünenthal haben sich auf ein Maßnahmenpaket geeinigt, um den Forschungs- und Entwicklungsbereich des Unternehmens neu aufzustellen. Die Reorganisation umfasst einen Abbau von 191 Vollzeitstellen in der Forschung und Entwicklung und 10 Vollzeitstellen im Bereich Finance. Betriebsbedingte Kündigungen sollen möglichst vermieden werden. Das Unternehmen plant, den Personalabbau durch interne Versetzungen, Altersteilzeitlösungen und ein Freiwilligenprogramm umzusetzen. Letzteres bietet finanzielle Anreize und externe Beratungsangebote, um Mitarbeiter bei einem Stellenwechsel zu unterstützen.


Madrid, Spain, 12 June 2019 – A pan-European survey initiated by Grünenthal and presented at this year’s annual European Congress of Rheumatology (EULAR 2019) in Madrid indicates that gout is being diagnosed late and is not controlled effectively or monitored regularly enough. Despite these significant gaps in the management of the disease, 8 out of 10 patients claim they are satisfied with their current treatment1.


Aachen, Germany, 8 May 2019 – Grünenthal intends to realign its research and development activities. Today, the Corporate Executive Board informed the workforce about the background of the intended changes.


Brussels/Aachen, 2 May 2019 – The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as part of the EFIC-Grünenthal Grant (E-G-G). With a total value of €200,000, this biennial grant supports young scientists in their quest to turn creative ideas into research projects that deliver life-changing pain management approaches.


Aachen, 17. April 2019 – Die Themen Ausbildung und Innovation standen am Mittwoch, 17. April 2019, im Mittelpunkt eines Treffens von Prof. Dr. Andreas Pinkwart, Minister für Wirtschaft, Innovation, Digitalisierung und Energie des Landes Nordrhein-Westfalen und der Geschäftsführung von Grünenthal in der Aachener Zentrale des forschenden Pharmaunternehmens. Im Anschluss sprach der Minister mit angehenden Chemikanten und Biologielaboranten im Ausbildungslabor von Grünenthal über ihren beruflichen Alltag.


Aachen, Germany, 22 January 2019– Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s Finance and IT organisation on 1 February 2019. Fabian currently leads Grünenthal’s Group Controlling and manages over 150 employees, including Finance staff in the affiliates.

Štěpán Kráčala, Head Global Communications, Grünenthal

Štěpán Kráčala

Head Global Communications

Grünenthal GmbH



Phone +49 241 569-1335

E-Mail Stepan.Kracala@grunenthal.com